Exhaled nitric oxide is not a biomarker for idiopathic pulmonary arterial hypertension or for treatment efficacy.
Exhaled nitric oxide
FeNO
Hypertention
Lungs
Journal
BMC pulmonary medicine
ISSN: 1471-2466
Titre abrégé: BMC Pulm Med
Pays: England
ID NLM: 100968563
Informations de publication
Date de publication:
29 Oct 2019
29 Oct 2019
Historique:
received:
20
03
2019
accepted:
09
10
2019
entrez:
31
10
2019
pubmed:
31
10
2019
medline:
9
4
2020
Statut:
epublish
Résumé
Idiopathic pulmonary arterial hypertension (IPAH) is a fatal illness. Despite many improvements in the treatment of these patients, there is no unique prognostic variable available to track these patients. The aim of this study was to evaluate the association between fractional exhaled nitric oxide (FeNO) levels, as a noninvasive biomarker, with disease severity and treatment outcome. Thirty-six patients (29 women and 7 men, mean age 38.4 ± 11.3 years) with IPAH referred to the outpatient's clinic of Masih Daneshvari Hospital, Tehran, Iran, were enrolled into this pilot observational study. Echocardiography, six-minute walking test (6MWT), FeNO, brain natriuretic peptide (BNP) levels and the functional class of patients was assessed before patients started treatment. Assessments were repeated after three months. 30 healthy non-IPAH subjects were recruited as control subjects. There was no significant difference in FeNO levels at baseline between patients with IPAH and subjects in the control group. There was also no significant increase in FeNO levels during the three months of treatment and levels did not correlate with other disease measures. In contrast, other markers of disease severity were correlated with treatment effect over the three months. FeNO levels are a poor non-invasive measure of IPAH severity and of treatment response in patients in this pilot study.
Sections du résumé
BACKGROUND
BACKGROUND
Idiopathic pulmonary arterial hypertension (IPAH) is a fatal illness. Despite many improvements in the treatment of these patients, there is no unique prognostic variable available to track these patients. The aim of this study was to evaluate the association between fractional exhaled nitric oxide (FeNO) levels, as a noninvasive biomarker, with disease severity and treatment outcome.
METHODS
METHODS
Thirty-six patients (29 women and 7 men, mean age 38.4 ± 11.3 years) with IPAH referred to the outpatient's clinic of Masih Daneshvari Hospital, Tehran, Iran, were enrolled into this pilot observational study. Echocardiography, six-minute walking test (6MWT), FeNO, brain natriuretic peptide (BNP) levels and the functional class of patients was assessed before patients started treatment. Assessments were repeated after three months. 30 healthy non-IPAH subjects were recruited as control subjects.
RESULTS
RESULTS
There was no significant difference in FeNO levels at baseline between patients with IPAH and subjects in the control group. There was also no significant increase in FeNO levels during the three months of treatment and levels did not correlate with other disease measures. In contrast, other markers of disease severity were correlated with treatment effect over the three months.
CONCLUSION
CONCLUSIONS
FeNO levels are a poor non-invasive measure of IPAH severity and of treatment response in patients in this pilot study.
Identifiants
pubmed: 31664957
doi: 10.1186/s12890-019-0954-z
pii: 10.1186/s12890-019-0954-z
pmc: PMC6819396
doi:
Substances chimiques
Antihypertensive Agents
0
Biomarkers
0
Nitric Oxide
31C4KY9ESH
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
188Commentaires et corrections
Type : ErratumIn
Références
J Am Coll Cardiol. 2003 Mar 19;41(6):1028-35
pubmed: 12651053
Clin Rheumatol. 2013 Oct;32(10):1519-31
pubmed: 23780636
Eur J Clin Invest. 2011 Aug;41(8):889-97
pubmed: 21554268
Circ Cardiovasc Imaging. 2014 Jan;7(1):107-14
pubmed: 24173272
Am J Respir Crit Care Med. 2005 Apr 15;171(8):912-30
pubmed: 15817806
J Am Coll Cardiol. 2002 Apr 3;39(7):1214-9
pubmed: 11923049
Eur J Clin Invest. 2006 Sep;36 Suppl 3:10-5
pubmed: 16919005
Am J Respir Crit Care Med. 2006 May 1;173(9):1023-30
pubmed: 16456139
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70
pubmed: 25712077
Thorax. 2002 Apr;57(4):361-3
pubmed: 11923558
Chest. 1997 Jan;111(1):44-50
pubmed: 8995991
Heart Fail Rev. 2017 May;22(3):289-297
pubmed: 28417295
Circulation. 2012 Jul 17;126(3):349-56
pubmed: 22696079
Eur Respir J. 2008 Aug;32(2):503-12
pubmed: 18669790
Pediatr Pulmonol. 2012 Jun;47(6):546-50
pubmed: 22038831
Eur Respir J. 2011 Jun;37(6):1386-91
pubmed: 20884742
Eur J Intern Med. 2007 Jul;18(4):272-82
pubmed: 17574100
Am J Respir Crit Care Med. 2005 Aug 1;172(3):352-7
pubmed: 15879413
Chest. 2007 Feb;131(2):402-9
pubmed: 17296640
Eur Respir J. 2017 Apr 26;49(4):
pubmed: 28446552
J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D42-50
pubmed: 24355641
Eur Respir J. 2007 Jul;30(1):104-9
pubmed: 17360728
Lung. 2001;179(4):233-43
pubmed: 11891614
Eur Respir J. 2007 May;29(5):944-50
pubmed: 17301100
Respir Res. 2006 Jun 30;7:94
pubmed: 16813647
J Am Heart Assoc. 2018 Feb 14;7(4):
pubmed: 29444773
Chest. 2000 Jan;117(1):19-24
pubmed: 10631193
J Card Fail. 2012 Oct;18(10):799-803
pubmed: 23040116
Radiographics. 2012 Jul-Aug;32(4):1085-7
pubmed: 22786995
Eur Respir J. 2010 May;35(5):1079-87
pubmed: 20032020
Respir Med. 2001 Feb;95(2):153-8
pubmed: 11217912
J Asthma. 2010 Sep;47(7):805-9
pubmed: 20670207
Free Radic Biol Med. 2004 Oct 1;37(7):1010-7
pubmed: 15336317
Circulation. 2010 Jul 13;122(2):164-72
pubmed: 20585012
Am J Respir Crit Care Med. 2011 Sep 1;184(5):602-15
pubmed: 21885636
N Engl J Med. 2002 Jun 27;346(26):2079-82
pubmed: 12087146
Eur Respir J. 2011 May;37(5):1096-103
pubmed: 20693249
Medicine (Baltimore). 2014 Dec;93(27):e256
pubmed: 25501096